epiberberine has been researched along with angiotensinogen in 1 studies
| Studies (epiberberine) | Trials (epiberberine) | Recent Studies (post-2010) (epiberberine) | Studies (angiotensinogen) | Trials (angiotensinogen) | Recent Studies (post-2010) (angiotensinogen) |
|---|---|---|---|---|---|
| 49 | 0 | 37 | 3,606 | 78 | 875 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, J; Gong, X; Gui, Z; Huang, J; Li, C; Li, X; Liu, Y; Xiao, Y; Ye, X; Zhang, Y | 1 |
1 other study(ies) available for epiberberine and angiotensinogen
| Article | Year |
|---|---|
Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway.
Topics: Angiotensinogen; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Gene Expression Regulation; Kidney; Male; Mesangial Cells; Mice, Obese; Molecular Docking Simulation; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2021 |